

Notice of References Cited

Application/Control No.

09/454,481

Applicant(s)/Patent Under
Reexamination
ALLISON ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 1 of 5

U.S. PATENT DOCUMENTS

*		Document Number	Date	Name	Classification	
		Country Code-Number-Kind Code	MM-YYYY			
	A	US-5,811,097-A	09-1998	Allison, JP, et al	424	144.1
	B	US-5,855,887-A	01-1999	Allison, JP, et al	424	144.1
	C	US-6,051,227-A	03-2000	Allison, JP, et al	424	144.1
	D	US- -				
	E	US- -				
	F	US- -				
	G	US- -				
	H	US- -				
	I	US- -				
	J	US- -				
	K	US- -				
	L	US- -				
	M	US- -				

FOREIGN PATENT DOCUMENTS

*		Document Number	Date	Country	Name	Classification	
		Country Code-Number-Kind Code	MM-YYYY				
	N	- -					
	O	- -					
	P	- -					
	Q	- -					
	R	- -					
	S	- -					
	T	- -					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)					
	U	Bodey, B, et al, Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, vol. 20, pp. 2665-2676					
	V	Timmerman, JM, et al, 1999, Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, vol. 50, pp. 507-529					
	W	Arceci, RJ, 1998, The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, vol. 76, pp. 80-93					
	X	Pardoll, DM, 1993, Cancer vaccines, Immunology Today, vol. 14, pp. 310-316					

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Rawlings
SR 5/18/01

Notice of References Cited

Application/Control No.

09/454,481

Applicant(s)/Patent Under
Reexamination
ALLISON ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 2 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US- -			
	B	US- -			
	C	US- -			
	D	US- -			
	E	US- -			
	F	US- -			
	G	US- -			
	H	US- -			
	I	US- -			
	J	US- -			
	K	US- -			
	L	US- -			
	M	US- -			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	- -				
	O	- -				
	P	- -				
	Q	- -				
	R	- -				
	S	- -				
	T	- -				

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
f	U	Lee, K-H, et al, 1999, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, vol. 163, pp. 6292-6300
u	V	Zaks, TZ, et al, 1998, Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Cancer Research, vol. 58, pp. 4902-4908
.	W	Zhu, J, et al, 2001, Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune neuritis in resistant mice, Journal of Neuroimmunology 115: 111-117
.	X	Yang, Y-F, et al, 1997, Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages, Cancer Research, vol. 57, pp. 4036-4041

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR 5/18/01

Notice of References Cited

Application/Control No.

09/454,481

Applicant(s)/Patent Under
Reexamination
ALLISON ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 3 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US- -			
	B	US- -			
	C	US- -			
	D	US- -			
	E	US- -			
	F	US- -			
	G	US- -			
	H	US- -			
	I	US- -			
	J	US- -			
	K	US- -			
	L	US- -			
	M	US- -			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	- -				
	O	- -				
	P	- -				
	Q	- -				
	R	- -				
	S	- -				
	T	- -				

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
i	U	Anderson, DE, et al, 2000, Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population, Nature Medicine, vol. 6, pp. 211-214
j	V	Leach, DR, et al, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, vol. 271, pp. 1734-1736
k	W	Chambers, CA, et al, 1997, Thymocyte development is normal in CTLA-4-deficient mice, Proceedings of the National Academy of Sciences USA, vol. 94, pp. 9296-9301
	X	Gribben, G, et al, 1994, Alloantigen and concomitant CTLA4 signaling induces clonal deletion of alloreactive T cells, Blood, vol. 84, pp. 397a (meeting abstract)

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

09/454,481

Applicant(s)/Patent Under
Reexamination
ALLISON ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 4 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US- -			
	B	US- -			
	C	US- -			
	D	US- -			
	E	US- -			
	F	US- -			
	G	US- -			
	H	US- -			
	I	US- -			
	J	US- -			
	K	US- -			
	L	US- -			
	M	US- -			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	- -				
	O	- -				
	P	- -				
	Q	- -				
	R	- -				
	S	- -				
	T	- -				

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Lewis, GD, et al, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness, Cancer Research, vol. 56, pp. 1457-1465
	V	Gao, P, et al, Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumors in combination with interleukin-12 treatment, Journal of Immunotherapy, vol. 23, pp. 643-653
	W	Sullivan, TJ, et al, 1998, Induction of CNS inflammatory disease as a consequence of CTLA-4/B7 blockade, FASEB Journal, vol. 12, pp. A1092 (meeting abstract)
	X	Sotomayor, EM, et al, 1999, In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance, Proceedings of the National Academy of Science USA, vol. 96, pp. 11476-11481

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR 5/18/01

Notice of References Cited

Application/Control No.

09/454,481

Applicant(s)/Patent Under
Reexamination
ALLISON ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 5 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US- -			
	B	US- -			
	C	US- -			
	D	US- -			
	E	US- -			
	F	US- -			
	G	US- -			
	H	US- -			
	I	US- -			
	J	US- -			
	K	US- -			
	L	US- -			
	M	US- -			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	- -				
	O	- -				
	P	- -				
	Q	- -				
	R	- -				
	S	- -				
	T	- -				

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Christadoss, P, et al, 2000, Animal models of myasthenia gravis, Clinical Immunology, vol. 94, pp. 75-87
	V	Sussman, JJ, et al, 1994, Activation of T lymphocytes for the adoptive immunotherapy of cancer, Annals of Surgical Oncology, vol. 1, pp. 296-306 (abstract only), MEDLINE <i>SR</i>
	W	Heslop, HE, 1994, Cytokine gene transfer in the therapy of malignancy, Baillieres Clinical Haematology, vol. 7, pp. 135-51 (abstract only), MEDLINE 8030497 <i>SR</i>
	X	Wallack, MK, et al, 1992, Active specific immunotherapy with vaccinia melanoma oncolysate, Mt. Sinai Journal of Medicine, vol. 59, pp. 227-233 (abstract only), MEDLINE 1340507 <i>SR</i>

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR 5/18/01

Notice of References Cited

Application/Control No.

09/454,481

Applicant(s)/Patent Under
Reexamination
ALLISON ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Art Unit

1642

Page 6 of 6

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US- -			
	B	US- -			
	C	US- -			
	D	US- -			
	E	US- -			
	F	US- -			
	G	US- -			
	H	US- -			
	I	US- -			
	J	US- -			
	K	US- -			
	L	US- -			
	M	US- -			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	- -				
	O	- -				
	P	- -				
	Q	- -				
	R	- -				
	S	- -				
	T	- -				

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
U		Krummel, MF, et al, 1996, Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo, Internation Immunology, vol. 8, pp. 519-523 (abstract only), BIOSIS 1996-283884
V		Walunas, TL, et al, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, vol. 1, pp. 405-413
W		Kearney, ER, et al, 1995, Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cell in vivo is dependent on CD28 costimulation and inhibited by CTLA-4, Journal of Immunology, vol. 155, pp. 1032-1036
X		

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR 5/18/01